Latest solid tumor cancers Stories
Initiation of Registrational Studies Planned for This Year MORRISTOWN, N.J., Jan.
Eleven-month Increase in Median OS Reported with VT-122 plus Sorafenib, Compared to Sorafenib Alone.
Company is First to Offer Plasma-Based Next Generation Sequencing Tests FORT MYERS, Fla., March 18, 2014 /PRNewswire/ -- NeoGenomics, Inc.
- A poem in which the author retracts something said in an earlier poem.